Scientific Director Jens J. Holst – University of Copenhagen

Forward this page to a friend Resize Print Bookmark and Share

Novo Nordisk Foundation Center for Basic Metabolic Research > Research > Section for Translational Metabolic Physiology > Translational Metabolic Physiology staff > Scientific Director Je...

Scientific Director Jens J. Holst

MD, DMSc, Professor  

Curriculum in Brief

Jens Juul Holst is presently professor of Medical Physiology at the Department of Biomedical Sciences at the faculty of Health Sciences, University of Copenhagen, where he is also the vice-chairman.

Since 2006 he has also been director of the Research Cluster for Diabetes and Obesity at the Faculty, and since 2010, Scientific Director at section for Translational Metabolic Physiology, Novo Nordisk Foundation Center for Basic Metabolic Research.

Professor Holst has pioneered the isolation and characterization of GLP-1 and discovery of the potential of GLP-1 for treatment of diabetes and obesity.

Awards and Honors

He is an elected member of the Royal Society of Science and Letters, and has received a number of awards including the Novo Nordisk Award, the Paul Langerhans Award of the German Diabetes Society, the Knud Lundbæk Award, the KFJ-award of Health Science Faculty of the University of Copenhagen, the Bagger-Sørensen Award, the prestigious Claude Bernard Award of the European Association of the Study of Diabetes, and the Nordic Fernström Prize, one of  the most prestigious medical prizes in the Nordic countries.

His research group is partner of the DANORC Centre for obesity research and the UNIK-consortium "Food, Fitness & Pharma". Professor Holst is currently member of the editorial boards of Regulatory peptides, Endocrinology, Journal of Clinical Endocrinology and Metabolism, the American Journal of Physiology, and Diabetes.

Research Profile

Dr. Holst's key discoveries includes the isolation and characterization of GLP-1, the discovery of the metabolic actions of GLP-1; the identification of the underlying endocrine disturbances of incretin function in diabetes and obesity; the discovery of the potential of GLP-1 for treatment of diabetes and obesity; the characterization of the metabolism of GLP-1 and of the particular importance of the dipeptidyl peptidase-4; the demonstration of the efficacy of DPP-4 stabilized analogues of GLP-1; and the demonstration of the potential of DPP-4 inhibitors for diabetes therapy.

Jens J. Holst has authored more than 1550 scientific papers (currently about 1230 listed in PubMed) which have received > 61.000 citations and he has an h-index of 123 (Web of Science).